{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T08:31:55Z","timestamp":1794299515023,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"A+ Trust, Auckland District Health Board, Auckland, NZ","award":["Grant No. 5461-PG-1204-007"],"award-info":[{"award-number":["Grant No. 5461-PG-1204-007"]}]},{"name":"Cancer Society NZ","award":["Grant No. 10\/08"],"award-info":[{"award-number":["Grant No. 10\/08"]}]},{"name":"Auckland Northland Cancer Society, NZ"},{"name":"Intramural Research Program of the Center for Cancer Research","award":["Grant Nos.ZIA BC010499"],"award-info":[{"award-number":["Grant Nos.ZIA BC010499"]}]},{"name":"Intramural Research Program of the Center for Cancer Research","award":["ZIA BC010624"],"award-info":[{"award-number":["ZIA BC010624"]}]},{"DOI":"10.13039\/501100004391","name":"the China Medical University","doi-asserted-by":"crossref","award":["Grant Nos. CMU108-MF-50"],"award-info":[{"award-number":["Grant Nos. CMU108-MF-50"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004391","name":"the China Medical University","doi-asserted-by":"crossref","award":["CMU109-MF-65"],"award-info":[{"award-number":["CMU109-MF-65"]}],"id":[{"id":"10.13039\/501100004391","id-type":"DOI","asserted-by":"crossref"}]},{"name":"GoodFellow Trust, Urology Department, Auckland Hospital, Auckland, NZ","award":["Grant No. +3192"],"award-info":[{"award-number":["Grant No. +3192"]}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"crossref","award":["Grant Nos. 108-2314-B-037-026-MY2"],"award-info":[{"award-number":["Grant Nos. 108-2314-B-037-026-MY2"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology of Taiwan","doi-asserted-by":"crossref","award":["108-2320-B-039-050-MY"],"award-info":[{"award-number":["108-2320-B-039-050-MY"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Kaohsiung Medical University Hospital","award":["Grant Nos. KMUH108-8R53"],"award-info":[{"award-number":["Grant Nos. KMUH108-8R53"]}]},{"name":"Kaohsiung Medical University Hospital","award":["KMUH108-8R55"],"award-info":[{"award-number":["KMUH108-8R55"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    It is being debated whether prostate-specific antigen (PSA)-based screening effectively reduces prostate cancer mortality. Some of the uncertainty could be related to deficiencies in the age-based PSA cut-off thresholds used in screening. Current study considered 2779 men with prostate cancer and 1606 men without a cancer diagnosis, recruited for various studies in New Zealand, US, and Taiwan. Association of PSA with demographic, lifestyle, clinical characteristics (for cases), and the\n                    <jats:italic>aldo\u2013keto reductase 1C3<\/jats:italic>\n                    (\n                    <jats:italic>AKR1C3<\/jats:italic>\n                    ) rs12529 genetic polymorphisms were analysed using multiple linear regression and univariate modelling. Pooled multivariable analysis of cases showed that PSA was significantly associated with demographic, lifestyle, and clinical data with an interaction between ethnicity and age further modifying the association. Pooled multivariable analysis of controls data also showed that demographic and lifestyle are significantly associated with PSA level. Independent case and control analyses indicated that factors associated with PSA were specific for each cohort. Univariate analyses showed a significant age and PSA correlation among all cases and controls except for the US-European cases while genetic stratification in cases showed variability of correlation. Data suggests that unique PSA cut-off thresholds factorized with demographics, lifestyle and genetics may be more appropriate for prostate cancer screening.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-04116-8","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T06:03:34Z","timestamp":1641535414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of factors associated with PSA level in prostate cancer cases and controls from three geographical regions"],"prefix":"10.1038","volume":"12","author":[{"given":"Nishi","family":"Karunasinghe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsion Zewdu","family":"Minas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo-Ying","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arier","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuotun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Masters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Goudie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Pin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynnette R.","family":"Ferguson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"4116_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/s0888-7543(05)80275-7","volume":"14","author":"PH Riegman","year":"1992","unstructured":"Riegman, P. H., Vlietstra, R. J., Suurmeijer, L., Cleutjens, C. B. & Trapman, J. Characterization of the human kallikrein locus. Genomics 14, 6\u201311. https:\/\/doi.org\/10.1016\/s0888-7543(05)80275-7 (1992).","journal-title":"Genomics"},{"key":"4116_CR2","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/0090-4295(93)90259-D","volume":"42","author":"A Bjartell","year":"1993","unstructured":"Bjartell, A. et al. Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. Urology 42, 502\u2013510 (1993).","journal-title":"Urology"},{"key":"4116_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.5455\/aim.2016.24.156-161","volume":"24","author":"A Prcic","year":"2016","unstructured":"Prcic, A., Begic, E. & Hiros, M. Usefulness of total PSA value in prostate diseases diagnosis. Acta Inform Med 24, 156\u2013161. https:\/\/doi.org\/10.5455\/aim.2016.24.156-161 (2016).","journal-title":"Acta Inform Med"},{"key":"4116_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3747\/co.v16i3.459","volume":"16","author":"RJ Ablin","year":"2009","unstructured":"Ablin, R. J. & Haythorn, M. R. Screening for prostate cancer: Controversy? What controversy?. Curr. Oncol. 16, 1\u20132. https:\/\/doi.org\/10.3747\/co.v16i3.459 (2009).","journal-title":"Curr. Oncol."},{"key":"4116_CR5","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jnci\/djr500","volume":"104","author":"GL Andriole","year":"2012","unstructured":"Andriole, G. L. et al. Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J. Natl. Cancer Inst. 104, 125\u2013132. https:\/\/doi.org\/10.1093\/jnci\/djr500 (2012).","journal-title":"J. Natl. Cancer Inst."},{"key":"4116_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s10552-012-9951-8","volume":"23","author":"R Gulati","year":"2012","unstructured":"Gulati, R. et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes Control 23, 827\u2013835. https:\/\/doi.org\/10.1007\/s10552-012-9951-8 (2012).","journal-title":"Cancer Causes Control"},{"key":"4116_CR7","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/978-3-642-45195-9_7","volume":"202","author":"FH Schroder","year":"2014","unstructured":"Schroder, F. H. ERSPC, PLCO studies and critique of cochrane review 2013. Recent Results Cancer Res. 202, 59\u201363. https:\/\/doi.org\/10.1007\/978-3-642-45195-9_7 (2014).","journal-title":"Recent Results Cancer Res."},{"key":"4116_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson, J. et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer. Eur. Urol. 76, 43\u201351. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.009 (2019).","journal-title":"Eur. Urol."},{"key":"4116_CR9","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1002\/cncr.31178","volume":"124","author":"HJ de Koning","year":"2018","unstructured":"de Koning, H. J. et al. The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials. Cancer 124, 1197\u20131206. https:\/\/doi.org\/10.1002\/cncr.31178 (2018).","journal-title":"Cancer"},{"key":"4116_CR10","doi-asserted-by":"publisher","unstructured":"Moyer, V. A. & US-Preventive-Services-Task-Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 157, 120\u2013134. https:\/\/doi.org\/10.7326\/0003-4819-157-2-201207170-00459 (2012).","DOI":"10.7326\/0003-4819-157-2-201207170-00459"},{"key":"4116_CR11","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4111\/icu.2017.58.6.423","volume":"58","author":"G Gejerman","year":"2017","unstructured":"Gejerman, G. et al. US Preventive Services Task Force prostate-specific antigen screening guidelines result in higher Gleason score diagnoses. Investig. Clin. Urol. 58, 423\u2013428. https:\/\/doi.org\/10.4111\/icu.2017.58.6.423 (2017).","journal-title":"Investig. Clin. Urol."},{"key":"4116_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10552-018-1014-3","volume":"29","author":"R Gilbert","year":"2018","unstructured":"Gilbert, R. et al. Developing new age-specific prostate-specific antigen thresholds for testing for prostate cancer. Cancer Causes Control 29, 383\u2013388. https:\/\/doi.org\/10.1007\/s10552-018-1014-3 (2018).","journal-title":"Cancer Causes Control"},{"key":"4116_CR13","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10552-020-01291-3","volume":"31","author":"S Harrison","year":"2020","unstructured":"Harrison, S. et al. Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigen. Cancer Causes Control 31, 431\u2013449. https:\/\/doi.org\/10.1007\/s10552-020-01291-3 (2020).","journal-title":"Cancer Causes Control"},{"key":"4116_CR14","doi-asserted-by":"publisher","unstructured":"Tarantino, G. et al. Clinical factors affecting prostate-specific antigen levels in prostate cancer patients undergoing radical prostatectomy: A retrospective study. Future Sci. OA 7, FSO643. https:\/\/doi.org\/10.2144\/fsoa-2020-0154 (2021).","DOI":"10.2144\/fsoa-2020-0154"},{"key":"4116_CR15","doi-asserted-by":"publisher","first-page":"101174","DOI":"10.1016\/j.pmedr.2020.101174","volume":"20","author":"DJ Press","year":"2020","unstructured":"Press, D. J. et al. Tobacco and marijuana use and their association with serum prostate-specific antigen levels among African American men in Chicago. Prev. Med. Rep. 20, 101174. https:\/\/doi.org\/10.1016\/j.pmedr.2020.101174 (2020).","journal-title":"Prev. Med. Rep."},{"key":"4116_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/s0090-4295(01)01305-x","volume":"58","author":"EP Gelmann","year":"2001","unstructured":"Gelmann, E. P. et al. Relationship of demographic and clinical factors to free and total prostate-specific antigen. Urology 58, 561\u2013566. https:\/\/doi.org\/10.1016\/s0090-4295(01)01305-x (2001).","journal-title":"Urology"},{"key":"4116_CR17","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1002\/ijc.27877","volume":"132","author":"L Zuccolo","year":"2013","unstructured":"Zuccolo, L. et al. Alcohol consumption and PSA-detected prostate cancer risk\u2014A case\u2013control nested in the ProtecT study. Int. J. Cancer 132, 2176\u20132185. https:\/\/doi.org\/10.1002\/ijc.27877 (2013).","journal-title":"Int. J. Cancer"},{"key":"4116_CR18","doi-asserted-by":"publisher","unstructured":"Gudmundsson, J. et al. Genetic correction of PSA values using sequence variants associated with PSA levels. Sci Transl Med 2, 62ra92. https:\/\/doi.org\/10.1126\/scitranslmed.3001513 (2010).","DOI":"10.1126\/scitranslmed.3001513"},{"key":"4116_CR19","doi-asserted-by":"publisher","first-page":"14248","DOI":"10.1038\/ncomms14248","volume":"8","author":"TJ Hoffmann","year":"2017","unstructured":"Hoffmann, T. J. et al. Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. Nat. Commun. 8, 14248. https:\/\/doi.org\/10.1038\/ncomms14248 (2017).","journal-title":"Nat. Commun."},{"key":"4116_CR20","doi-asserted-by":"publisher","unstructured":"Benafif, S., Kote-Jarai, Z., Eeles, R. A. & Practical-Consortium. A review of prostate cancer genome-wide association studies (GWAS). Cancer Epidemiol. Biomark. Prev. 27, 845\u2013857. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-1046 (2018).","DOI":"10.1158\/1055-9965.EPI-16-1046"},{"key":"4116_CR21","doi-asserted-by":"publisher","unstructured":"Hishida, A. et al. Genome-wide association study of serum prostate-specific antigen levels based on 1000 Genomes imputed data in Japanese: The Japan Multi-Institutional Collaborative Cohort Study. Nagoya J. Med. Sci. 83, 183\u2013194. https:\/\/doi.org\/10.18999\/nagjms.83.1.183 (2021).","DOI":"10.18999\/nagjms.83.1.183"},{"key":"4116_CR22","doi-asserted-by":"publisher","first-page":"4568","DOI":"10.1038\/s41467-018-06920-9","volume":"9","author":"J Gudmundsson","year":"2018","unstructured":"Gudmundsson, J. et al. Genome-wide associations for benign prostatic hyperplasia reveal a genetic correlation with serum levels of PSA. Nat. Commun. 9, 4568. https:\/\/doi.org\/10.1038\/s41467-018-06920-9 (2018).","journal-title":"Nat. Commun."},{"key":"4116_CR23","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1002\/pros.24070","volume":"80","author":"W Li","year":"2020","unstructured":"Li, W. et al. Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels. Prostate 80, 1405\u20131412. https:\/\/doi.org\/10.1002\/pros.24070 (2020).","journal-title":"Prostate"},{"key":"4116_CR24","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1200\/JCO.2010.31.2405","volume":"29","author":"M Yang","year":"2011","unstructured":"Yang, M. et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 29, 2565\u20132573. https:\/\/doi.org\/10.1200\/JCO.2010.31.2405 (2011).","journal-title":"J. Clin. Oncol."},{"key":"4116_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jcb.20228","volume":"93","author":"J Kim","year":"2004","unstructured":"Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. J. Cell Biochem. 93, 233\u2013241. https:\/\/doi.org\/10.1002\/jcb.20228 (2004).","journal-title":"J. Cell Biochem."},{"key":"4116_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000336605","volume":"6","author":"R Werner","year":"2012","unstructured":"Werner, R. et al. Testosterone synthesis in patients with 17beta-hydroxysteroid dehydrogenase 3 deficiency. Sex Dev. 6, 161\u2013168. https:\/\/doi.org\/10.1159\/000336605 (2012).","journal-title":"Sex Dev."},{"key":"4116_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2174\/1568009617666170330115722","volume":"17","author":"N Karunasinghe","year":"2017","unstructured":"Karunasinghe, N., Masters, J., Flanagan, J. U. & Ferguson, L. R. Influence of Aldo-keto Reductase 1C3 in Prostate Cancer\u2014A mini review. Curr. Cancer Drug Targets 17, 603\u2013616. https:\/\/doi.org\/10.2174\/1568009617666170330115722 (2017).","journal-title":"Curr. Cancer Drug Targets"},{"key":"4116_CR28","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1038\/srep01528","volume":"3","author":"F Ishizaki","year":"2013","unstructured":"Ishizaki, F. et al. Androgen deprivation promotes intratumoral synthesis of dihydrotestosterone from androgen metabolites in prostate cancer. Sci. Rep. 3, 1528. https:\/\/doi.org\/10.1038\/srep01528 (2013).","journal-title":"Sci. Rep."},{"key":"4116_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.2174\/10022","volume":"11","author":"N Karunasinghe","year":"2013","unstructured":"Karunasinghe, N. et al. Androgen pathway related gene variants and prostate cancer association in Auckland men. Curr. Pharmacogenom. Person Med. 11, 22\u201330. https:\/\/doi.org\/10.2174\/10022 (2013).","journal-title":"Curr. Pharmacogenom. Person Med."},{"key":"4116_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/pros.20362","volume":"66","author":"RO Roberts","year":"2006","unstructured":"Roberts, R. O. et al. Polymorphisms in genes involved in sex hormone metabolism may increase risk of benign prostatic hyperplasia. Prostate 66, 392\u2013404. https:\/\/doi.org\/10.1002\/pros.20362 (2006).","journal-title":"Prostate"},{"key":"4116_CR31","doi-asserted-by":"publisher","first-page":"e0217373","DOI":"10.1371\/journal.pone.0217373","volume":"14","author":"N Karunasinghe","year":"2019","unstructured":"Karunasinghe, N. et al. Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand. PLoS ONE 14, e0217373. https:\/\/doi.org\/10.1371\/journal.pone.0217373 (2019).","journal-title":"PLoS ONE"},{"key":"4116_CR32","doi-asserted-by":"publisher","first-page":"e0199122","DOI":"10.1371\/journal.pone.0199122","volume":"13","author":"N Karunasinghe","year":"2018","unstructured":"Karunasinghe, N. et al. Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts. PLoS ONE 13, e0199122. https:\/\/doi.org\/10.1371\/journal.pone.0199122 (2018).","journal-title":"PLoS ONE"},{"key":"4116_CR33","unstructured":"Karunasinghe, N. & Ferguson, L. R. Supplementation of 200 micro grams\/d Selenium as Selenized Yeast for Six Months in a Male Cohort From Auckland, New Zealand to be Monitored with Biomarker Variation With and Without Genetic Stratification. http:\/\/www.ANZCTR.org.au\/ACTRN12619001106123.aspx (2019)."},{"key":"4116_CR34","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12263-011-0259-1","volume":"7","author":"N Karunasinghe","year":"2012","unstructured":"Karunasinghe, N. et al. Serum selenium and single-nucleotide polymorphisms in genes for selenoproteins: Relationship to markers of oxidative stress in men from Auckland, New Zealand. Genes Nutr. 7, 179\u2013190. https:\/\/doi.org\/10.1007\/s12263-011-0259-1 (2012).","journal-title":"Genes Nutr."},{"key":"4116_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1158\/1055-9965.EPI-16-1027","volume":"26","author":"CJ Smith","year":"2017","unstructured":"Smith, C. J. et al. Aspirin use reduces the risk of aggressive prostate cancer and disease recurrence in African-American Men. Cancer Epidemiol. Biomark. Prev. 26, 845\u2013853. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-1027 (2017).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"4116_CR36","doi-asserted-by":"publisher","first-page":"e54627","DOI":"10.1371\/journal.pone.0054627","volume":"8","author":"CC Yu","year":"2013","unstructured":"Yu, C. C. et al. Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer. PLoS ONE 8, e54627. https:\/\/doi.org\/10.1371\/journal.pone.0054627 (2013).","journal-title":"PLoS ONE"},{"key":"4116_CR37","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1158\/1055-9965.EPI-09-0665","volume":"18","author":"SP Huang","year":"2009","unstructured":"Huang, S. P. et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol. Biomark. Prev. 18, 3068\u20133074. https:\/\/doi.org\/10.1158\/1055-9965.EPI-09-0665 (2009).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"4116_CR38","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1039\/c6mb00873a","volume":"13","author":"V Vaidyanathan","year":"2017","unstructured":"Vaidyanathan, V. et al. Environmental factors and risk of aggressive prostate cancer among a population of New Zealand men\u2014A genotypic approach. Mol. Biosyst. 13, 681\u2013698. https:\/\/doi.org\/10.1039\/c6mb00873a (2017).","journal-title":"Mol. Biosyst."},{"key":"4116_CR39","unstructured":"National-Library-of-Medicine. Reference SNP (rs) Report rs12529. https:\/\/www.ncbi.nlm.nih.gov\/snp\/rs12529?vertical_tab=true (2021)."},{"key":"4116_CR40","unstructured":"R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing (Vienna, Austria, 2021)."},{"key":"4116_CR41","unstructured":"ggplot2: Elegant Graphics for Data Analysis (Springer, 2016)."},{"key":"4116_CR42","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/pros.22699","volume":"73","author":"AB Murphy","year":"2013","unstructured":"Murphy, A. B. et al. Smoking and prostate cancer in a multi-ethnic cohort. Prostate 73, 1518\u20131528. https:\/\/doi.org\/10.1002\/pros.22699 (2013).","journal-title":"Prostate"},{"key":"4116_CR43","doi-asserted-by":"publisher","first-page":"105562","DOI":"10.1016\/j.jsbmb.2019.105562","volume":"198","author":"R Scragg","year":"2020","unstructured":"Scragg, R. The Vitamin D Assessment (ViDA) study\u2014Design and main findings. J. Steroid Biochem. Mol. Biol. 198, 105562. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105562 (2020).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"4116_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1440-1827.2012.02794.x","volume":"62","author":"YJ Kuo","year":"2012","unstructured":"Kuo, Y. J., Lin, S. F., Chang, Y. H. & Pan, C. C. Trends in prostate needle biopsy diagnosis. A ten year experience of a medical center in Taiwan. Pathol. Int. 62, 191\u2013198. https:\/\/doi.org\/10.1111\/j.1440-1827.2012.02794.x (2012).","journal-title":"Pathol. Int."},{"key":"4116_CR45","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12894-016-0137-7","volume":"16","author":"D Shenoy","year":"2016","unstructured":"Shenoy, D., Packianathan, S., Chen, A. M. & Vijayakumar, S. Do African-American men need separate prostate cancer screening guidelines?. BMC Urol. 16, 19. https:\/\/doi.org\/10.1186\/s12894-016-0137-7 (2016).","journal-title":"BMC Urol."},{"key":"4116_CR46","first-page":"206","volume":"22","author":"DA Scaramuzzino","year":"2007","unstructured":"Scaramuzzino, D. A., Schulte, K., Mack, B. N., Soriano, T. F. & Fritsche, H. A. Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at \u2212 70 degrees C or less. Int. J. Biol. Mark. 22, 206\u2013213 (2007).","journal-title":"Int. J. Biol. Mark."},{"key":"4116_CR47","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1177\/1724600818789414","volume":"33","author":"V Simanek","year":"2018","unstructured":"Simanek, V. et al. Stability of total prostate-specific antigen and free prostate-specific antigen after 10 years\u2019 storage. Int. J. Biol. Mark. 33, 463\u2013466. https:\/\/doi.org\/10.1177\/1724600818789414 (2018).","journal-title":"Int. J. Biol. Mark."},{"key":"4116_CR48","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1373\/clinchem.2005.050641","volume":"52","author":"D Ulmert","year":"2006","unstructured":"Ulmert, D. et al. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin. Chem. 52, 235\u2013239. https:\/\/doi.org\/10.1373\/clinchem.2005.050641 (2006).","journal-title":"Clin. Chem."},{"key":"4116_CR49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/s0090-4295(00)00873-6","volume":"57","author":"KA Cooney","year":"2001","unstructured":"Cooney, K. A. et al. Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. Urology 57, 91\u201396. https:\/\/doi.org\/10.1016\/s0090-4295(00)00873-6 (2001).","journal-title":"Urology"},{"key":"4116_CR50","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1200\/JCO.2016.66.7527","volume":"34","author":"MA Preston","year":"2016","unstructured":"Preston, M. A. et al. Baseline prostate-specific antigen levels in midlife predict lethal prostate cancer. J. Clin. Oncol. 34, 2705\u20132711. https:\/\/doi.org\/10.1200\/JCO.2016.66.7527 (2016).","journal-title":"J. Clin. Oncol."},{"key":"4116_CR51","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/jrh.12127","volume":"32","author":"Z Obertova","year":"2016","unstructured":"Obertova, Z., Hodgson, F., Scott-Jones, J., Brown, C. & Lawrenson, R. Rural-urban differences in prostate-specific antigen (PSA) screening and its outcomes in New Zealand. J. Rural Health 32, 56\u201362. https:\/\/doi.org\/10.1111\/jrh.12127 (2016).","journal-title":"J. Rural Health"},{"key":"4116_CR52","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13000-016-0478-2","volume":"11","author":"J Gordetsky","year":"2016","unstructured":"Gordetsky, J. & Epstein, J. Grading of prostatic adenocarcinoma: Current state and prognostic implications. Diagn. Pathol. 11, 25. https:\/\/doi.org\/10.1186\/s13000-016-0478-2 (2016).","journal-title":"Diagn. Pathol."},{"issue":"Suppl 1","key":"4116_CR53","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.1186\/1753-6561-1-s1-s114","volume":"1","author":"HW Uh","year":"2007","unstructured":"Uh, H. W. et al. Model selection based on logistic regression in a highly correlated candidate gene region. BMC Proc. 1(Suppl 1), S114. https:\/\/doi.org\/10.1186\/1753-6561-1-s1-s114 (2007).","journal-title":"BMC Proc."},{"key":"4116_CR54","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41379-019-0292-y","volume":"32","author":"K Miyai","year":"2019","unstructured":"Miyai, K. et al. Histological differences in cancer cells, stroma, and luminal spaces strongly correlate with in vivo MRI-detectability of prostate cancer. Mod. Pathol. 32, 1536\u20131543. https:\/\/doi.org\/10.1038\/s41379-019-0292-y (2019).","journal-title":"Mod. Pathol."},{"key":"4116_CR55","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.yrtph.2010.05.006","volume":"61","author":"DC Mariner","year":"2011","unstructured":"Mariner, D. C., Ashley, M., Shepperd, C. J., Mullard, G. & Dixon, M. Mouth level smoke exposure using analysis of filters from smoked cigarettes: A study of eight countries. Regul. Toxicol. Pharmacol. 61, S39-50. https:\/\/doi.org\/10.1016\/j.yrtph.2010.05.006 (2011).","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"4116_CR56","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1021\/tx500298n","volume":"27","author":"TM Penning","year":"2014","unstructured":"Penning, T. M. Human aldo-keto reductases and the metabolic activation of polycyclic aromatic hydrocarbons. Chem. Res. Toxicol. 27, 1901\u20131917. https:\/\/doi.org\/10.1021\/tx500298n (2014).","journal-title":"Chem. Res. Toxicol."},{"issue":"Suppl 1","key":"4116_CR57","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.1080\/14622200310001649478","volume":"6","author":"PS Gardiner","year":"2004","unstructured":"Gardiner, P. S. The African Americanization of menthol cigarette use in the United States. Nicotine Tob. Res. 6(Suppl 1), S55-65. https:\/\/doi.org\/10.1080\/14622200310001649478 (2004).","journal-title":"Nicotine Tob. Res."},{"key":"4116_CR58","doi-asserted-by":"publisher","first-page":"20799","DOI":"10.1038\/s41598-020-77816-2","volume":"10","author":"JJ Song","year":"2020","unstructured":"Song, J. J. et al. Transcriptomic analysis of tobacco-flavored E-cigarette and menthol-flavored E-cigarette exposure in the human middle ear. Sci. Rep. 10, 20799. https:\/\/doi.org\/10.1038\/s41598-020-77816-2 (2020).","journal-title":"Sci. Rep."},{"key":"4116_CR59","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/j.juro.2011.11.086","volume":"187","author":"J Li","year":"2012","unstructured":"Li, J., Thompson, T., Joseph, D. A. & Master, V. A. Association between smoking status, and free, total and percent free prostate specific antigen. J. Urol. 187, 1228\u20131233. https:\/\/doi.org\/10.1016\/j.juro.2011.11.086 (2012).","journal-title":"J. Urol."},{"key":"4116_CR60","doi-asserted-by":"publisher","unstructured":"Lima, N. G., Soares Dde, F. & Rhoden, E. L. Importance of prostate-specific antigen (PSA) as a predictive factor for concordance between the Gleason scores of prostate biopsies and RADICAL prostatectomy specimens. Clinics (Sao Paulo) 68, 820\u2013824. https:\/\/doi.org\/10.6061\/clinics\/2013(06)16 (2013).","DOI":"10.6061\/clinics\/2013(06)16"},{"key":"4116_CR61","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clgc.2018.12.003","volume":"17","author":"T Suresh","year":"2019","unstructured":"Suresh, T. et al. Patient characteristics at prostate cancer diagnosis in different races at an academic center serving a diverse population. Clin. Genitourin. Cancer 17, 139\u2013144. https:\/\/doi.org\/10.1016\/j.clgc.2018.12.003 (2019).","journal-title":"Clin. Genitourin. Cancer"},{"key":"4116_CR62","doi-asserted-by":"publisher","unstructured":"Dickerman, B. A. et al. A metabolomics analysis of adiposity and advanced prostate cancer risk in the health professionals follow-up study. Metabolites 10. https:\/\/doi.org\/10.3390\/metabo10030099 (2020).","DOI":"10.3390\/metabo10030099"},{"key":"4116_CR63","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1002\/cncr.20856","volume":"103","author":"J Baillargeon","year":"2005","unstructured":"Baillargeon, J. et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 103, 1092\u20131095. https:\/\/doi.org\/10.1002\/cncr.20856 (2005).","journal-title":"Cancer"},{"key":"4116_CR64","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/jcsm.12446","volume":"10","author":"PJ Owen","year":"2019","unstructured":"Owen, P. J. et al. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer. J. Cachexia Sarcopenia Muscle 10, 1036\u20131044. https:\/\/doi.org\/10.1002\/jcsm.12446 (2019).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"4116_CR65","doi-asserted-by":"publisher","unstructured":"Brawley, O. W., Thompson, I. M., Jr. & Gronberg, H. Evolving recommendations on prostate cancer screening. Am. Soc. Clin. Oncol. Educ. Book 35, e80\u2013e87. https:\/\/doi.org\/10.14694\/EDBK_157413 (2016).","DOI":"10.14694\/EDBK_157413"},{"key":"4116_CR66","doi-asserted-by":"publisher","first-page":"E265","DOI":"10.1111\/j.1464-410X.2012.11766.x","volume":"112","author":"JJ Oh","year":"2013","unstructured":"Oh, J. J. et al. Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy. BJU Int. 112, E265-271. https:\/\/doi.org\/10.1111\/j.1464-410X.2012.11766.x (2013).","journal-title":"BJU Int."},{"key":"4116_CR67","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/pcan.2009.53","volume":"13","author":"IA Hekal","year":"2010","unstructured":"Hekal, I. A. & Ibrahiem, E. I. Obesity-PSA relationship: A new formula. Prostate Cancer Prostatic Dis. 13, 186\u2013190. https:\/\/doi.org\/10.1038\/pcan.2009.53 (2010).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"4116_CR68","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/pros.20704","volume":"68","author":"A Rundle","year":"2008","unstructured":"Rundle, A. & Neugut, A. I. Obesity and screening PSA levels among men undergoing an annual physical exam. Prostate 68, 373\u2013380. https:\/\/doi.org\/10.1002\/pros.20704 (2008).","journal-title":"Prostate"},{"key":"4116_CR69","doi-asserted-by":"publisher","unstructured":"Wang, B. et al. AKR1C3, a crucial androgenic enzyme in prostate cancer, promotes epithelial-mesenchymal transition and metastasis through activating ERK signaling. Urol. Oncol. 36, 472 e411-472 e420. https:\/\/doi.org\/10.1016\/j.urolonc.2018.07.005 (2018).","DOI":"10.1016\/j.urolonc.2018.07.005"},{"key":"4116_CR70","doi-asserted-by":"publisher","unstructured":"Shiota, M. et al. Polymorphisms in androgen metabolism genes with serum testosterone levels and prognosis in androgen-deprivation therapy. Urol. Oncol. 38, 849 e811-849 e818. https:\/\/doi.org\/10.1016\/j.urolonc.2020.06.033 (2020).","DOI":"10.1016\/j.urolonc.2020.06.033"},{"key":"4116_CR71","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/carcin\/bgn163","volume":"29","author":"JD Figueroa","year":"2008","unstructured":"Figueroa, J. D. et al. Bladder cancer risk and genetic variation in AKR1C3 and other metabolizing genes. Carcinogenesis 29, 1955\u20131962. https:\/\/doi.org\/10.1093\/carcin\/bgn163 (2008).","journal-title":"Carcinogenesis"},{"key":"4116_CR72","doi-asserted-by":"publisher","first-page":"163","DOI":"10.4103\/UROS.UROS_89_19","volume":"31","author":"CH Lin","year":"2020","unstructured":"Lin, C. H. et al. The value of prostate-specific antigen-age volume score in predicting prostate cancer in Taiwan. Urol. Sci. 31, 163\u2013169 (2020).","journal-title":"Urol. Sci."},{"key":"4116_CR73","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jcma.2012.02.001","volume":"75","author":"CW Yang","year":"2012","unstructured":"Yang, C. W. et al. Does extended prostate needle biopsy improve the concordance of Gleason scores between biopsy and prostatectomy in the Taiwanese population?. J. Chin. Med. Assoc. 75, 97\u2013101. https:\/\/doi.org\/10.1016\/j.jcma.2012.02.001 (2012).","journal-title":"J. Chin. Med. Assoc."},{"key":"4116_CR74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1373\/clinchem.2005.059170","volume":"52","author":"C Stephan","year":"2006","unstructured":"Stephan, C. et al. Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: An update. Clin. Chem. 52, 59\u201364. https:\/\/doi.org\/10.1373\/clinchem.2005.059170 (2006).","journal-title":"Clin. Chem."},{"key":"4116_CR75","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1258\/000456304323019578","volume":"41","author":"MA Gray","year":"2004","unstructured":"Gray, M. A., Cooke, R. R., Weinstein, P. & Nacey, J. N. Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000. Ann. Clin. Biochem. 41, 207\u2013212. https:\/\/doi.org\/10.1258\/000456304323019578 (2004).","journal-title":"Ann. Clin. Biochem."},{"key":"4116_CR76","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.clinbiochem.2014.06.006","volume":"47","author":"S De Keukeleire","year":"2014","unstructured":"De Keukeleire, S., Wauters, A., Luyts, D., Chandler, C. & Piqueur, M. Analytical performance of the VITROS(R) Immunodiagnostic Products total PSA II and free PSA assays. Clin. Biochem. 47, 1323\u20131325. https:\/\/doi.org\/10.1016\/j.clinbiochem.2014.06.006 (2014).","journal-title":"Clin. Biochem."},{"key":"4116_CR77","unstructured":"Wesgard-QC. Desirable Biological Variation Database specifications. https:\/\/www.westgard.com\/biodatabase1.htm (2019)."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04116-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04116-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:31:59Z","timestamp":1669300319000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04116-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4116"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04116-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-714389\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,7]]},"assertion":[{"value":"14 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}